A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
Conditions: Mantle Cell Lymphoma Interventions: Drug: Orelabrutinib; Drug: Bendamustine Injection; Drug: Rituximab; Drug: Orelabrutinib Placebo Sponsors: InnoCare Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Conditions: Relapsed or Refractory Follicular Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab; Drug: Prednisone; Drug: Bendamustine; Drug: Lenalidomide; Drug: Fludarabine; Drug: Liso-cel Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Drug: FT819; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Bendamustine Sponsors: Fate Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Conditions: Hodgkin Lymphoma Interventions: Other: observational Sponsors: Federico II University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Conditions: Myeloma Multiple Interventions: Drug: Bortezomib-bendamustine-melphalan Sponsors: Uppsala University; Uppsala County Council, Sweden; Dalarna County Council, Sweden Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Conditions: Advanced Solid Tumor Interventions: Drug: FT825; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Bendamustine; Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab Sponsors: Fate Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell Interventions: Biological: Liso-cel; Drug: Idelalisib; Drug: Rituximab; Drug: Bendamustine; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Conditions: B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia Interventions: Biological: Autologous BAFFR-tar...
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Conditions: Follicular Lymphoma (FL) Interventions: Drug: Epcoritamab; Drug: Prednisone; Drug: Rituximab; Drug: Lenalidomide; Drug: Doxorubicin; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Obinutuzumab; Drug: Bendamustine Sponsors: AbbVie; Genmab Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Conditions: Hodgkin Lymphoma Interventions: Biological: JS004 in combination with Toripalimab; Drug: Bendamustine or gemcitabine Sponsors: Shanghai Junshi Bioscience Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle-Cell Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Bendamustin Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Conditions: Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 Interventions: Drug: Bendamustine; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Bridge Therapy; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Leukapheresis; Procedure: Multigated Acquisition Scan; Biological: T-cell Receptor-engineered T-cells; Procedure: X-Ray Imaging Sponsors: Fred Hutchinson Cancer Center; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Conditions: Follicular Lymphoma (FL) Interventions: Drug: Odronextamab; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone/prednisolone; Drug: Bendamustine Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Conditions: Lymphoma Interventions: Drug: Obinutuzumab; Drug: Glofitamab; Drug: Rituximab; Drug: Bendamustine; Drug: Lenalidomide; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Conditions: Metastatic Colorectal Adenocarcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Bendamustine; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: M ultigated Acquisition Scan; Procedure:...
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
